Breast Imaging

Which Imaging Study Is Best for Axillary Staging in Early Breast Cancer with Positive Nodes?

·
Which Imaging Study Is Best for Axillary Staging in Early Breast Cancer with Positive Nodes?

A 52-year-old female sits in your clinic exam room, recently having received a diagnosis of a 1.5 cm invasive ductal carcinoma in her left breast. Her diagnostic mammogram and tomosynthesis are complete. On your physical exam, you palpate a firm, 1 cm mobile lymph node in her left axilla, a finding that makes you clinically suspicious for nodal involvement. The crucial next step is to accurately stage the axilla, as this will fundamentally guide surgical and systemic therapy decisions. The question is which imaging study to order first. For this specific presentation—a small primary tumor with clinically positive nodes—the American College of Radiology (ACR) designates axillary ultrasound as the Usually Appropriate initial imaging examination.

Who Fits This Clinical Scenario for Axillary Staging?

This guidance applies to a very specific patient profile: a female with a newly diagnosed primary breast cancer where the tumor is 2 cm or less in its greatest dimension, and—critically—there is a palpable or otherwise clinically suspicious lymph node in the ipsilateral axilla. The initial diagnostic breast imaging (mammography or digital breast tomosynthesis) has already been performed, establishing the primary cancer diagnosis.

It is essential to distinguish this situation from similar but distinct clinical presentations that follow different diagnostic pathways:

  • Clinically Node-Negative Patients: If the same patient with a <2 cm tumor had no suspicious findings on her axillary physical exam, the initial approach would be different, often proceeding directly to sentinel lymph node biopsy without preoperative imaging.
  • Larger Primary Tumors: For patients with breast cancers larger than 2 cm, even if clinically node-negative, the pretest probability of nodal metastases is higher, which can alter the imaging recommendations.
  • Palpable Axillary Lump without a Known Breast Primary: If a patient presents first with a palpable axillary lump and no known breast cancer, the differential diagnosis is broader, and the imaging workup starts differently to identify a potential primary source.

This article focuses exclusively on the patient with a small, known breast primary and a clinically suspicious axillary node.

What Diagnoses Are You Working Up in This Scenario?

The primary goal of imaging in this context is to confirm or refute the clinical suspicion of nodal metastasis and, if confirmed, to provide a target for tissue sampling. The differential diagnosis is narrow but has significant therapeutic implications.

Metastatic Breast Carcinoma
This is, by far, the most likely and most important diagnosis to confirm. The presence of a suspicious axillary node on physical exam in a patient with a known ipsilateral breast cancer strongly suggests metastatic spread. Confirming this with imaging and subsequent biopsy is critical for accurate staging (e.g., converting a clinical N1 (cN1) to a pathologic N1 (pN1)). This confirmation directly impacts treatment, potentially obviating the need for a sentinel lymph node biopsy and guiding the decision toward an axillary lymph node dissection or targeted axillary dissection, as well as influencing choices for systemic therapy.

Reactive Lymphadenopathy
Less commonly, an enlarged axillary lymph node can be reactive or inflammatory, unrelated to the malignancy. Causes can range from minor skin infections on the arm to systemic inflammatory conditions. While less probable in this specific clinical context, it remains a possibility. Imaging helps differentiate benign-appearing reactive nodes (which typically retain their oval shape and fatty hilum) from morphologically suspicious malignant nodes.

Second Malignancy (e.g., Lymphoma)
While rare, it is possible for the palpable axillary node to represent a different, synchronous malignancy such as lymphoma. This is very low on the differential, but imaging features that are atypical for breast cancer metastases might raise this suspicion, prompting a core biopsy rather than a fine-needle aspiration to ensure adequate tissue for a full pathologic evaluation, including flow cytometry if needed.

Why Is Axillary Ultrasound the Recommended Study for This Presentation?

The ACR designates axillary ultrasound (US) as Usually Appropriate because it is the most direct, efficient, and safest tool to answer the primary clinical question: is the suspicious node morphologically abnormal, and can we obtain a tissue diagnosis?

The key advantage of ultrasound is its dual diagnostic and interventional capability. It provides excellent spatial resolution to assess lymph node morphology for signs of malignancy, such as cortical thickening, a rounded shape, and effacement or loss of the central fatty hilum. More importantly, if a suspicious node is identified, ultrasound provides real-time guidance for a percutaneous biopsy—either a fine-needle aspiration (FNA) or a core needle biopsy—during the same appointment. This ability to move immediately from imaging to tissue sampling is a powerful workflow advantage, providing a definitive pathologic answer quickly and avoiding delays in treatment planning.

From a safety perspective, ultrasound involves no ionizing radiation (0 mSv) and does not require intravenous contrast, eliminating risks of allergic reaction or contrast-induced nephropathy.

Why Other Studies Are Rated Lower for This Initial Step

  • MRI breast without and with IV contrast: Rated as May be appropriate (Disagreement), this study is highly sensitive for detecting abnormal-appearing lymph nodes. However, it is not the primary tool for initial tissue diagnosis. It is more costly, requires more time, and cannot be used to guide a biopsy in the same way as ultrasound. The “Disagreement” indicates that while some centers may use breast MRI for comprehensive staging of the breast and axilla, it is not universally considered the first-line test for evaluating a clinically positive node.
  • FDG-PET/CT skull base to mid-thigh: Rated as Usually not appropriate for this specific scenario. PET/CT is a powerful tool for detecting distant metastatic disease, but it is generally reserved for patients with higher-risk disease (e.g., larger tumors, multiple positive nodes, or inflammatory breast cancer). For a small primary tumor with a single clinically positive node, the risk of distant metastases is lower, and the use of a high-radiation (☢☢☢☢ 10-30 mSv), high-cost systemic staging study is not justified as the initial step.

What’s Next After Axillary Ultrasound? Downstream Workflow

The results of the axillary ultrasound and any subsequent biopsy will direct the next steps in management. The workflow branches based on the findings.

If Ultrasound and Biopsy Are Positive for Metastasis:
A positive biopsy confirms pathologic nodal involvement (pN1). This patient will typically proceed to definitive treatment, which may include neoadjuvant (preoperative) chemotherapy, followed by surgery. The surgical plan for the axilla is altered; instead of a sentinel lymph node biopsy, the patient may undergo an axillary lymph node dissection (ALND) or a targeted axillary dissection (TAD), where the biopsy-proven positive node is marked with a clip and specifically removed along with sentinel nodes.

If Ultrasound Is Negative (No Suspicious Nodes Seen):
If ultrasound fails to identify any morphologically suspicious lymph nodes, the clinical suspicion from the physical exam is not confirmed by imaging. In this case, the patient is typically managed as clinically node-negative. The standard of care would then be to proceed with a surgical sentinel lymph node biopsy (SLNB) at the time of their breast surgery to pathologically stage the axilla.

If Ultrasound Shows a Suspicious Node, but Biopsy Is Negative:
This scenario creates discordance between imaging and pathology. The suspicious-appearing node may be reactive, or the biopsy may have been a false negative. The standard approach here is to place a clip in the biopsied (but pathologically negative) node and proceed with a targeted axillary dissection or sentinel node biopsy that includes removal of this specific clipped node for definitive pathologic assessment.

Pitfalls to Avoid (and When to Get Help)

Navigating this workflow requires attention to a few common pitfalls to ensure accurate staging and appropriate patient care.

  • Incomplete Axillary Survey: Ensure the sonographer performs a comprehensive ultrasound of all three axillary levels, as metastases can sometimes skip Level I.
  • Accepting a Non-Diagnostic FNA: If a fine-needle aspiration is performed and returns as “insufficient for diagnosis,” it should not be treated as a negative result. A repeat biopsy, often with a core needle, is necessary.
  • Forgetting to Clip a Biopsied Node: If a biopsy is performed, a marker clip should always be placed in the node. This is crucial for localization during future surgery, especially if the patient receives neoadjuvant chemotherapy which may shrink the node and make it difficult to find later.

If there is discordance between clinical, imaging, and pathologic findings, always discuss the case in a multidisciplinary tumor board meeting with breast surgeons, radiologists, pathologists, and oncologists to determine the best path forward.

Related ACR Topics and Tools

For a comprehensive overview of all clinical scenarios related to axillary imaging, or to explore the technical details and safety considerations of the recommended studies, the following resources are available.

Frequently Asked Questions

Why not just go straight to sentinel lymph node biopsy (SLNB) if I already feel a node?

If a palpable node is positive for cancer, the patient is not a candidate for a standard SLNB alone and will likely need a more extensive axillary surgery or neoadjuvant therapy. Performing a preoperative ultrasound-guided biopsy confirms the nodal status non-invasively. If positive, it allows for better surgical planning (e.g., axillary dissection or targeted dissection) and can spare the patient an unnecessary SLNB procedure that would be followed by a second, more extensive axillary surgery.

Is a fine-needle aspiration (FNA) sufficient, or is a core needle biopsy required for the axillary node?

For many institutions, a positive FNA confirming metastatic carcinoma is sufficient for treatment planning. However, a core needle biopsy provides more tissue, can reduce the rate of non-diagnostic samples, and is essential if there’s any suspicion of another disease like lymphoma. A core biopsy is also needed to assess hormone receptor status on the metastasis, which can be important if it differs from the primary tumor. The choice often depends on institutional preference and the specific clinical situation.

If the axillary ultrasound is positive, should I also order a PET/CT for systemic staging?

For this specific scenario (tumor ≤ 2 cm and a single clinically positive node), a PET/CT is rated ‘Usually not appropriate’ as the initial step. The risk of distant metastatic disease is still relatively low. Systemic staging with PET/CT is typically reserved for patients with higher-risk disease, such as those with larger tumors (>5 cm), four or more positive axillary nodes, or inflammatory breast cancer. The decision to order a PET/CT is best made after the full local-regional staging is complete and in consultation with a medical oncologist.

What if the primary tumor was slightly larger, for instance, 2.5 cm?

If the primary tumor is larger than 2 cm, even with clinically positive nodes, the scenario changes. The pretest probability of a higher nodal burden and distant disease increases. While axillary ultrasound remains the first step to confirm the nodal status, the threshold to consider further systemic staging with CT or PET/CT may be lower. This falls under a different variant in the ACR Appropriateness Criteria for a ‘Newly diagnosed breast cancer, greater than 2 cm, with clinical node-positive’.

Does breast MRI replace the need for a dedicated axillary ultrasound?

No. While breast MRI provides excellent images of the axilla and is highly sensitive for detecting abnormal nodes, it is not a substitute for a dedicated diagnostic and interventional axillary ultrasound. Ultrasound allows for real-time dynamic assessment and, most importantly, immediate biopsy guidance. If a breast MRI is performed for other reasons (e.g., assessing disease extent in the breast) and shows a suspicious axillary node, the next step is typically a targeted second-look ultrasound to find and biopsy that node.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026